Evaluation of the Proposed FDA Pilot Dose-Response Methodology for Topical Corticosteroid Bioequivalence Testing
- 1 January 1997
- journal article
- clinical trial
- Published by Springer Nature in Pharmaceutical Research
- Vol. 14 (3) , 303-308
Abstract
Purpose. The American FDA has recently released a Guidance document for topical corticosteroid bioequivalence testing. The purpose of this study was to evaluate the recommendations of this document for appropriateness. The new specifications require a dose-vasoconstriction response estimation by the use of a Minolta chromameter in a preliminary pilot study to determine the parameters for use in a pivotal bioequivalence study. Methods. The visually-assessed human skin blanching assay methodology routinely practiced in our laboratories was modified to comply with the requirements of the pilot study so that visual and chromameter data could be compared. Two different cream formulations, each containing 0.12% betamethasone 17-valerate, were used for this comparison. Results. Visual data showed the expected rank order of AUC values for most dose durations whereas the chromameter data did not show similar results. The expected rank order of AUC values for both chromameter and visual data was not observed at very short dose durations. In fitting the data to pharmacodynamic models, equivalent goodness of fit criteria were obtained when several different parameter estimates were used in the model definition, however the visual data were best described by the sigmoid Emax model while the chromameter data were best described by the simple Emax model. Conclusions. The Emax values predicted by the models were close to the observed values for both data sets and, in addition, excellent correlation between the AUC values and the maximum blanching response (Rmax) (r > 0.95) was noted for both methods of assessment. The chromameter ED50 values determined in this study were approximately 2 hours for both preparations. At this dose duration the instrument would not be sensitive enough to distinguish between weak blanching responses and normal skin for bioequivalence assessment purposes.Keywords
This publication has 9 references indexed in Scilit:
- A comparison of techniques to assess skin blanching following the topical application of glucocorticoids.1996
- Circadian Activity of Topical 0.05% Betamethasone Dipropionate in Human Skin In VivoJournal of Investigative Dermatology, 1994
- Sensitivity of different areas of the flexor aspect of the human forearm to corticosteroid-induced skin blanchingBritish Journal of Dermatology, 1992
- Quantitative Skin Blanching Assay of Corticosteroid Creams Using Tristimulus Colour AnalysisJournal of Pharmacy and Pharmacology, 1992
- Topical corticosteroid-induced skin blanching measurement: eye or instrument?Archives of Dermatology, 1991
- BLANCHING ACTIVITIES OF BETAMETHASONE FORMULATIONS - THE EFFECT OF DOSAGE FORM ON TOPICAL DRUG AVAILABILITY1990
- 'Vasoconstriction'--skin blanching--assay for glucocorticoids--a critiqueArchives of Dermatology, 1989
- Potency classification of topical corticosteroids: modern perspectives.1989
- Are generic formulations equivalent to trade name topical glucocorticoids?Archives of Dermatology, 1987